The complaint alleges that Defendants violated Sections 10(b), 14(e) and 20(a) of the Securities Exchange Act of 1934.
Juno is a biopharmaceutical company founded in 2013 that is developing cell-based cancer immunotherapies. JCAR015 is its leading product candidate, is currently in clinical trials.
The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding Juno's business, operational and compliance policies. Particularly, Defendants made false and/or misleading statements and/or partial disclosures regarding JCAR015's safety and made public misrepresentations or failed to disclose material facts of the death of patients in its Phase 2 clinical trial.
In May 2016, a patient in the Phase 2 trial of JCAR015 died of a cerebral edema, a form of neurotoxicity. Two additional patients in the ROCKET trial died of cerebral edemas by early July, causing the FDA to issue a clinical hold which forced Defendants to reveal the truth on July 7, 2016, post-market. Following this news, Juno's stock dropped $13.01 per share, or 31.87%, to close at $27.81 on July 8, 2016.
No Class has yet been certified in the above action. To discuss this action, or for any questions, please visit the firm's site: http://www.bgandg.com/#!juno/c3onh or contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email firstname.lastname@example.org. Those who inquire by e-mail are encouraged to include their mailing address and telephone number. If you suffered a loss in Juno, you have until September 12, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | email@example.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/deadline-alert--updated-class-period---bronstein-gewirtz--grossman-llc-reminds-shareholders-of-class-action-against-juno-therapeutics-inc-juno--lead-plaintiff-deadline-september-12-2016-300326033.html
SOURCE Bronstein, Gewirtz & Grossman, LLC